Monique Young, NP
Acute Care · Metairie, LANPI 1902197700
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,308 of the $10,156 with a category attached, or 72.0%. 33 manufacturers reported payments, led by Medtronic at 31.8% of the total. Reporting peaked in 2024 at $2,915 and has fallen 55.5% since, to $1,296 in 2025. Among acute care clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $34.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$1K
- Biosense Webster, Inc.$1K
- Novartis$808
- Impulse Dynamics (USA) Inc.$495
- Johnson & Johnson$413
- plus $3K from 27 others
What the payments were for
- Consulting fees$3003%
- Speaking & faculty fees$8709%
- Travel & lodging$1,66016%
- Food & beverage$7,30872%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 37 | $3,226 |
| Boston Scientific | 23 | $1,481 |
| Biosense Webster, Inc. | 30 | $1,179 |
| Novartis | 47 | $808 |
| Impulse Dynamics (USA) Inc. | 3 | $495 |
| Johnson & Johnson | 25 | $413 |
| E.r. Squibb & Sons, L.L.C. | 18 | $318 |
| Novo Nordisk | 14 | $283 |
| Pfizer | 18 | $280 |
| Merck | 11 | $207 |
| Amgen | 10 | $185 |
| Esperion Therapeutics, Inc. | 9 | $163 |
| AstraZeneca | 10 | $147 |
| Abbott | 3 | $136 |
| Shockwave Medical, Inc | 1 | $104 |
| Sanofi-aventis U.S. LLC | 4 | $90 |
| Boehringer Ingelheim | 5 | $85 |
| Kestra Medical Technology Services, Inc. | 3 | $74 |
| Lilly USA, LLC | 4 | $65 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $55 |
| Bayer | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Edwards Lifesciences | 1 | $30 |
| GSK | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Cardiva Medical, Inc. | 1 | $25 |
| AbbVie | 1 | $24 |
| Haemonetics Corporation | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Atricure, Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,156 in reported general payments places this provider in the 95th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $112,269 |
| XareltoRivaroxaban | 22 | $21,304 |
| SotalolSotalol Hcl | 44 | $843 |
| Flecainide Acetate | 18 | $638 |
| Metoprolol Succinate | 46 | $586 |
| Amiodarone Hcl | 31 | $557 |
| Pantoprazole Sodium | 110 | $512 |
| Colchicine | 12 | $190 |
| Atorvastatin Calcium | 18 | $171 |
| Furosemide | 102 | $153 |
| Losartan Potassium | 11 | $98 |
| Spironolactone | 11 | $54 |
| Carvedilol | 13 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $280 | $112,269102 claims |
| Johnson & JohnsonXarelto | $413 | $21,30422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 acute care providers in Louisiana.
Other acute care in Metairie
- Valerie BernardMetairie$6K
- Edward CollierMetairie$3K
- Precious HodgesLafayette$70K
- Brinton FegleyShreveport$61K
- Charles JarreauNew Orleans$40K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
- Jeremy TerroLafayette$11K
- Mary HireShreveport$11K
- Jacquelyn CosterHouma$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.